Market Report Source

Overview

As the GIT Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as Crohn’s disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transformation, growth rates may remain low due to the increased availability of effective generic medicines and fewer launches of innovative new drugs.

‘The Gastrointestinal Market Outlook to 2012’ is a new report published by Business Insights that provides a detailed epidemiological analysis of key indications within major GIT markets, and examines the factors impacting their prevalence. The dynamics of the market are examined through an analysis of leading brands within each indication and a profile of the pharma companies and market trends influencing the sales of GIT treatments. Forecasts for major product sales over the 2006-12 period are also provided.

Table of Contents

Executive Summary
Patient potential of GIT therapeutic area
Global market analysis
Pipeline analysis
Competitive landscape

Chapter 1 Patient potential of GIT
therapeutic area
Summary
Introduction
Gastroesophageal reflux disorder
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Peptic ulcer disease
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Irritable bowel syndrome
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Ulcerative colitis
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Crohn’s disease
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology

Chapter 2 Global market analysis
Summary
Introduction
Market analysis by country
Licensing trends
Market analysis by drug class
Leading brand dynamics
Key events in the GIT market
Gastroesophageal reflux disorder and peptic ulcer disease
Leading brands of the GERD/PUD market
Proton pump inhibitor market analysis
Market dynamics
Key brands analysis
Histamine-2 receptor antagonist market analysis
Market dynamics
Key brands analysis
GERD/PUD sales forecasts to 2012
Irritable bowel syndrome
Competitive dynamics of IBS subclasses
Leading brands of the IBS market
GI sensorimotor modulators market analysis
Market dynamics
Key brands analysis
Antispasmodics/anticholinergics
Market dynamics
IBS sales forecasts to 2012
Inflammatory bowel disease: Crohn’s disease and ulcerative colitis
Competitive dynamics of Crohn’s disease and ulcerative colitis subclasses
Leading brands of IBD subclasses
Immunosuppressants market analysis
Market dynamics
Key brands analysis
Anti-rheumatic agents
Market dynamics
Key brands analysis
Intestinal anti-inflammatory agents
Market dynamics
Key brands analysis
IBD sales forecasts to 2012
Total GIT sales forecasts to 2012

Chapter 3 Pipeline analysis
Summary
Introduction
Key trends in R&D
Increasing penetration of generics in the GERD/PUD market will continue to limit R&D investment
Continuing, yet uncertain focus on drug development in irritable bowel syndrome
Emerging therapies for the management of inflammatory bowel disease
New mechanism of action
The GIT therapeutic area pipeline
Leading drugs in development
Profiles of key pipeline products
Phase II compounds
tetomilast (OPC-6535)
Alicaforsen (ISIS 2302)
OX-17
S-tenatoprazole-Na
Phase III compounds
Renzapride
Kremezin (AST-120)
Cimzia (certolizumab pegol)
TAK-390MR (dexlansoprazole)
Orencia (abatacept)
Drugs in registration
Ramosetron
Recently marketed drugs
Amitiza (lubiprostone)
Pipeline forecasts
Factors affecting forecasts
GIT pipeline forecasts

Chapter 4 Competitive landscape
Summary
Introduction
Market share
AstraZeneca
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Wyeth
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Abbott
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Johnson & Johnson
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Takeda
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Novartis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Astellas
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Eisai
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Altana
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints
Procter & Gamble
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline
Strategic analysis
Sales and promotions
Growth drivers
Growth constraints

Chapter 5 Appendix
IMS data
Licensing status
Index
Index

List of Figures
Figure 2.1: Global GIT market share by geography, 2006
Figure 2.2: Licensing status of global GIT sales, 2005-06 ($bn)
Figure 2.3: Competitive dynamics of the global GIT market by drug class, 2006
Figure 2.4: Competitive dynamics of the leading 10 brands in the global GIT market, 2005-06
Figure 2.5: Competitive dynamics of the global GERD/PUD market, 2005-06
Figure 2.6: Competitive dynamics of the leading 10 brands in the global GERD/PUD market, 2005-06
Figure 2.7: Competitive dynamics of the global IBS market, 2005-06
Figure 2.8: Competitive dynamics of the leading 10 brands in the global IBS market, 2005-06
Figure 2.9: Competitive dynamics of the global IBD market, 2005-06
Figure 2.10: Competitive dynamics of the leading 10 brands in the global IBD market, 2005-06
Figure 3.11: Prevailing R&D approaches
Figure 3.12: The GIT pipeline by indication and stage of development, 2006
Figure 3.13: Recently launched products and late-stage R&D compounds indicated for the GIT therapeutic area, 2006
Figure 4.14: Competitive dynamics of the leading players in the global GIT market, 2006
Figure 4.15: AstraZeneca’s GIT sales, 2006 ($m)
Figure 4.16: Wyeth’s GIT sales, 2006 ($m)
Figure 4.17: Abbott’s GIT sales, 2006 ($m)
Figure 4.18: J&J’s GIT sales, 2006 ($m)
Figure 4.19: Takeda’s GIT sales, 2006 ($m)
Figure 4.20: Novartis’ GIT sales, 2006 ($m)
Figure 4.21: Astellas’ GIT sales, 2006 ($m)
Figure 4.22: Eisai’s GIT sales, 2006 ($m)
Figure 4.23: Altana’s GIT sales, 2006 ($m)
Figure 4.24: P&G’s GIT sales, 2006 ($m)

List of Tables
Table 1.1: Estimated prevalence of major GIT indications in the seven major pharmaceutical markets, 2006
Table 1.2: Estimated prevalence of GERD across the seven major markets, 2006
Table 1.3: Forecast epidemiology of GERD across the seven major markets, 2006-12
Table 1.4: Estimated prevalence of PUD in the seven major pharmaceutical markets, 2006
Table 1.5: Forecast epidemiology of PUD across the seven major markets, 2006-12
Table 1.6: Estimated prevalence of IBS in the seven major pharmaceutical markets, 2006
Table 1.7: Forecast epidemiology of IBS across the seven major markets, 2006-12
Table 1.8: Estimated prevalence of ulcerative colitis in the seven major pharmaceutical markets, 2006
Table 1.9: Estimated epidemiology of UC across the seven major markets, 2006–12
Table 1.10: Estimated prevalence of Crohn’s disease in the seven major pharmaceutical markets, 2006
Table 1.11: Forecast prevalence of Crohn’s disease across the seven major markets, 2006–12
Table 2.12: Market size ($m) and growth (%) of drug classes within the global GIT market, 2002-06
Table 2.13: Market size ($m) and growth (%) of leading brands in the global GIT market, 2005
Table 2.14: Market size ($m) and growth (%) of drug classes within the global GERD and PUD market, 2002-06
Table 2.15: Market size ($m) and growth (%) of leading GERD/PUD products, 2005–06
Table 2.16: GERD/PUD sales forecast, 2006-12 ($m)
Table 2.17: Market size (US$) and growth (%) of drug classes within the global IBS market, 2002-06
Table 2.18: Market size ($m) and growth (%) of leading IBS brands, 2005–06
Table 2.19: IBS sales forecast, 2006-12 ($m)
Table 2.20: Market Share ($m) and growth (%) of drug classes within the global IBD market, 2002-06
Table 2.21: Market size ($m) and growth (%) of leading IBD brands, 2005–06
Table 2.22: IBD sales forecast, 2006-12 ($m)
Table 2.23: GIT therapeutic sales forecasts by drug class, 2006-12 ($m)
Table 3.24: GIT pipeline sales forecasts, 2006-12 ($m)
Table 4.25: Market share ($m) and growth (%) of leading corporations in the global GIT market, 2005-06
Table 4.26: AstraZeneca’s GIT portfolio sales, 2005-06 ($m)
Table 4.27: AstraZeneca’s R&D product pipeline, 2006
Table 4.28: Promotional spend on major GIT drugs by AstraZeneca, 2005-06 ($m)
Table 4.29: Wyeth’s GIT portfolio sales, 2005-06 ($m)
Table 4.30: Wyeth’s R&D product pipeline, 2006
Table 4.31: Promotional spend on major GIT drugs by Wyeth, 2005-06 ($m)
Table 4.32: Abbott’s GIT portfolio sales, 2005-06 ($m)
Table 4.33: Abbott’s R&D product pipeline, 2006
Table 4.34: Promotional spend on major GIT drugs by Abbott, 2005-06 ($m)
Table 4.35: J&J’s GIT portfolio sales, 2005-06 ($m)
Table 4.36: J&J’s R&D product pipeline, 2006
Table 4.37: Promotional spend on major drugs by J&J, 2005-06 ($m)
Table 4.38: Takeda’s GIT portfolio sales, 2005-06 ($m)
Table 4.39: Takeda’s R&D product pipeline, 2006
Table 4.40: Promotional spend on major drugs by Takeda, 2005-06
Table 4.41: Novartis’ GIT portfolio sales, 2005-06 ($m)
Table 4.42: Novartis’ R&D product pipeline, 2006
Table 4.43: Promotional spend on major drugs by Novartis, 2005-06 ($m)
Table 4.44: Astellas’ GIT portfolio sales, 2005-06 ($m)
Table 4.45: Astellas’ R&D product pipeline, 2006
Table 4.46: Promotional spend on major drugs by Astellas, 2005-06
Table 4.47: Eisai’s GIT portfolio sales, 2005-06 ($m)
Table 4.48: Eisai’s R&D product pipeline, 2006
Table 4.49: Promotional spend on major drugs by Eisai, 2005-06
Table 4.50: Altana’s GIT portfolio sales, 2005-06 ($m)
Table 4.51: Promotional spend on major drugs by Altana, 2005-06
Table 4.52: P&G’s GIT portfolio sales, 2005-06 ($m)
Table 4.53: P&G’s R&D product pipeline, 2006